Mikael C. I. Karlsson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mikael C. I. Karlsson has a total of 381 co-authors. Here are the top co-authors by number of shared publications:
- Susanne Gabrielsson
Division of Immunology and Respiratory Medicine, Department of Medicine Solna Karolinska Institutet Stockholm Sweden
32 shared publications - Andreas Lundqvist
Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden
31 shared publications - Annemarijn Offens
Division of Immunology and Allergy, Department of Medicine, Karolinska Institutet, Solna, Stockholm, Sweden
31 shared publications - Gözde Güclüler Akpinar
Division of Immunology and Allergy, Department of Medicine, Karolinska Institutet, Solna, Stockholm, Sweden
31 shared publications - Loïc Steiner
Division of Immunology and Respiratory Medicine, Department of Medicine Solna Karolinska Institutet Stockholm Sweden
31 shared publications - Pia Larssen
Division of Immunology and Allergy, Department of Medicine, Karolinska Institutet, Solna, Stockholm, Sweden
31 shared publications
Latest Publications
- Open Access
- 27 July 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 7410
Cancer immunotherapy targeting murine myeloid cells requires endosomal pattern recognition
Immunotherapy is now an established and efficient treatment option for many cancer patients. However, a proportion of patients still experience poor outcomes due to treatment resistance. Thus, a clear understanding of key mechanisms of resistance is needed for the development of new treatments. Here, we employ mouse models to explore an immunotherapeutic approach based on anti-MARCO (αMARCO) and anti-PD-L1 (αPD-L1) antibody-mediated targeting of tumor-associated macrophages (TAM). We demonstrate that effective immunotherapy relies on a functional endosomal pattern recognition machinery. We determine that endosomal Toll-like receptors (TLR), specifically TLR9, precondition macrophages to respond to αMARCO treatment by regulating the transcription of inflammasome components. Absence of TLRs renders TAMs unresponsive to treatment while retaining an immunosuppressive phenotype. Thus, we uncover the intracellular TLR signalling as a feature of immunotherapy efficacy, required to sensitise TAMs to treatment, and indicate that TLR targeting could be exploited to improve immunotherapeutic outcomes.
- 27 July 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 7410
Open AccessCancer immunotherapy targeting murine myeloid cells requires endosomal pattern recognition
Immunotherapy is now an established and efficient treatment option for many cancer patients. However, a proportion of patients still experience poor outcomes due to treatment resistance. Thus, a clear understanding of key mechanisms of resistance is needed for the development of new treatments. Here, we employ mouse models to explore an immunotherapeutic approach based on anti-MARCO (αMARCO) and anti-PD-L1 (αPD-L1) antibody-mediated targeting of tumor-associated macrophages (TAM). We demonstrate that effective immunotherapy relies on a functional endosomal pattern recognition machinery. We determine that endosomal Toll-like receptors (TLR), specifically TLR9, precondition macrophages to respond to αMARCO treatment by regulating the transcription of inflammasome components. Absence of TLRs renders TAMs unresponsive to treatment while retaining an immunosuppressive phenotype. Thus, we uncover the intracellular TLR signalling as a feature of immunotherapy efficacy, required to sensitise TAMs to treatment, and indicate that TLR targeting could be exploited to improve immunotherapeutic outcomes.
- Open Access
Intratumoral expression of JAML on NK cells is controlled by tumor microenvironment and MHC class I interaction
JAML is an adhesion molecule known to promote T cell activation and T cell-mediated tumor rejection. In the current study, we show that JAML expression is enriched on mouse intratumoral NK cells compared with splenic NK cells. JAML+ NK cells were associated with tissue residency and co-expressed the immune checkpoints PD-1 and LAG3. JAML expression could be induced on splenic NK cells by IL-2 and further enhanced by IL-21. JAML levels were inversely correlated with inhibitory signaling, as NK cells expressing self-recognizing Ly49 receptors had reduced JAML expression, suggesting regulation of JAML expression by MHC class I molecules. Interaction with the JAML ligand CXADR also reduced JAML surface expression, indicating that tumor-mediated membrane stripping may represent a mechanism of immunoediting. Although JAML RNA transcripts were detectable in human NK cells, JAML protein was found only intracellularly. Together, these findings identify the JAML-CXADR interaction as a potential regulatory pathway in NK cell-mediated killing of tumors.
Open AccessIntratumoral expression of JAML on NK cells is controlled by tumor microenvironment and MHC class I interaction
JAML is an adhesion molecule known to promote T cell activation and T cell-mediated tumor rejection. In the current study, we show that JAML expression is enriched on mouse intratumoral NK cells compared with splenic NK cells. JAML+ NK cells were associated with tissue residency and co-expressed the immune checkpoints PD-1 and LAG3. JAML expression could be induced on splenic NK cells by IL-2 and further enhanced by IL-21. JAML levels were inversely correlated with inhibitory signaling, as NK cells expressing self-recognizing Ly49 receptors had reduced JAML expression, suggesting regulation of JAML expression by MHC class I molecules. Interaction with the JAML ligand CXADR also reduced JAML surface expression, indicating that tumor-mediated membrane stripping may represent a mechanism of immunoediting. Although JAML RNA transcripts were detectable in human NK cells, JAML protein was found only intracellularly. Together, these findings identify the JAML-CXADR interaction as a potential regulatory pathway in NK cell-mediated killing of tumors.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Antigen-Loaded Extracellular Vesicles Induce Responsiveness to Anti–PD-1 and Anti–PD-L1 Treatment in a Checkpoint Refractory Melanoma Model
Gating strategy for OVA-specific CD8 T cells in splenocytes
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Antigen-Loaded Extracellular Vesicles Induce Responsiveness to Anti–PD-1 and Anti–PD-L1 Treatment in a Checkpoint Refractory Melanoma Model
Gating strategy for OVA-specific CD8 T cells in splenocytes
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Figure 4 from Antigen-Loaded Extracellular Vesicles Induce Responsiveness to Anti–PD-1 and Anti–PD-L1 Treatment in a Checkpoint Refractory Melanoma Model
Prophylactic administration of EVs and subsequent injection of checkpoint blockade results in a combination effect and improves survival. A, Mice were injected with EVs intravenously before they received OVA-expressing B16 melanoma intraperitoneally, to induce memory T-cell responses as indicated. The mice were sacrificed when tumors reached 1,000 mm3. B, Survival was plotted using the Kaplan–Meier survival curve. C, After inoculation, tumors were measured every 2 to 3 days, and individual tumor growth curves for each group were plotted. Numbers at the bottom right represent surviving mice of the total mice in each group. D, At the endpoint, tumors were collected and analyzed for immune cell infiltration using flow cytometry. Immune cells were identified as CD45+ cells and B16 melanoma cells as CD45–. E, B16 melanoma cells were analyzed for surface MHC class I and PD-L1 expression. F, The frequency of infiltrating of total, CD8+ and antigen-specific T cells in tumors was analyzed by flow cytometry. G, PD-1 expression on the infiltrating CD8+ T cells was determined using flow cytometry. Graphs show the results of two independent experiments. The experiment included 7 to 12 mice per group, of which 4 to 8 mice per group qualified for flow cytometric analysis of the tumor. Dots represent a single mouse, and data are presented as the mean ± SD. Data were analyzed using the Kruskal–Wallis test with Dunn test for multiple comparisons. The Mantel–Cox test was applied for the survival curve. *, P <0.05; **, P < 0.01; and ***, P < 0.001.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from Antigen-Loaded Extracellular Vesicles Induce Responsiveness to Anti–PD-1 and Anti–PD-L1 Treatment in a Checkpoint Refractory Melanoma Model
Prophylactic administration of EVs and subsequent injection of checkpoint blockade results in a combination effect and improves survival. A, Mice were injected with EVs intravenously before they received OVA-expressing B16 melanoma intraperitoneally, to induce memory T-cell responses as indicated. The mice were sacrificed when tumors reached 1,000 mm3. B, Survival was plotted using the Kaplan–Meier survival curve. C, After inoculation, tumors were measured every 2 to 3 days, and individual tumor growth curves for each group were plotted. Numbers at the bottom right represent surviving mice of the total mice in each group. D, At the endpoint, tumors were collected and analyzed for immune cell infiltration using flow cytometry. Immune cells were identified as CD45+ cells and B16 melanoma cells as CD45–. E, B16 melanoma cells were analyzed for surface MHC class I and PD-L1 expression. F, The frequency of infiltrating of total, CD8+ and antigen-specific T cells in tumors was analyzed by flow cytometry. G, PD-1 expression on the infiltrating CD8+ T cells was determined using flow cytometry. Graphs show the results of two independent experiments. The experiment included 7 to 12 mice per group, of which 4 to 8 mice per group qualified for flow cytometric analysis of the tumor. Dots represent a single mouse, and data are presented as the mean ± SD. Data were analyzed using the Kruskal–Wallis test with Dunn test for multiple comparisons. The Mantel–Cox test was applied for the survival curve. *, P <0.05; **, P < 0.01; and ***, P < 0.001.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Antigen-Loaded Extracellular Vesicles Induce Responsiveness to Anti–PD-1 and Anti–PD-L1 Treatment in a Checkpoint Refractory Melanoma Model
Gating strategy for MHCI+ and PD-L1+ tumor cells and intratumoral PD-1+ and pentamer+ T cells
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Antigen-Loaded Extracellular Vesicles Induce Responsiveness to Anti–PD-1 and Anti–PD-L1 Treatment in a Checkpoint Refractory Melanoma Model
Gating strategy for MHCI+ and PD-L1+ tumor cells and intratumoral PD-1+ and pentamer+ T cells
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from Antigen-Loaded Extracellular Vesicles Induce Responsiveness to Anti–PD-1 and Anti–PD-L1 Treatment in a Checkpoint Refractory Melanoma Model
Mean growth curve of tumors in prophylactic setting and percentage of T cells in splenocytes of mice with vs without tumor development
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from Antigen-Loaded Extracellular Vesicles Induce Responsiveness to Anti–PD-1 and Anti–PD-L1 Treatment in a Checkpoint Refractory Melanoma Model
Mean growth curve of tumors in prophylactic setting and percentage of T cells in splenocytes of mice with vs without tumor development
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Figure 1 from Antigen-Loaded Extracellular Vesicles Induce Responsiveness to Anti–PD-1 and Anti–PD-L1 Treatment in a Checkpoint Refractory Melanoma Model
Characterization of BMDC-derived EVs. BMDC-derived EVs were characterized using multiple methods. A, Morphologic analysis of EVs was performed by TEM. Two different magnifications are shown. B, Five EV batches, shown individually, were subjected to NTA analysis to determine EV size (nm), and a mean and mode size 184 and 157 nm, respectively was measured. C, EVs were bound to anti-CD9–coated magnetic beads, stained for surface markers as indicated, and detected by flow cytometry. The data are shown as the mean fluorescence intensity ratio between the specific antibody and its corresponding isotype control. A signal above 1 (dotted line) was considered positive. Data are presented as mean ± SD, n = 6. D, Western blot analysis was performed on proteins extracted from the five EV batches for the presence of MHC class II and OVA. E, The presence of OVA on the surface of EVs was determined by ELISA. Data are shown as the mean ± SEM, n = 8.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Antigen-Loaded Extracellular Vesicles Induce Responsiveness to Anti–PD-1 and Anti–PD-L1 Treatment in a Checkpoint Refractory Melanoma Model
Characterization of BMDC-derived EVs. BMDC-derived EVs were characterized using multiple methods. A, Morphologic analysis of EVs was performed by TEM. Two different magnifications are shown. B, Five EV batches, shown individually, were subjected to NTA analysis to determine EV size (nm), and a mean and mode size 184 and 157 nm, respectively was measured. C, EVs were bound to anti-CD9–coated magnetic beads, stained for surface markers as indicated, and detected by flow cytometry. The data are shown as the mean fluorescence intensity ratio between the specific antibody and its corresponding isotype control. A signal above 1 (dotted line) was considered positive. Data are presented as mean ± SD, n = 6. D, Western blot analysis was performed on proteins extracted from the five EV batches for the presence of MHC class II and OVA. E, The presence of OVA on the surface of EVs was determined by ELISA. Data are shown as the mean ± SEM, n = 8.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Antigen-Loaded Extracellular Vesicles Induce Responsiveness to Anti–PD-1 and Anti–PD-L1 Treatment in a Checkpoint Refractory Melanoma Model
Upregulation of functional markers on DCs after in vitro exposure to EVs.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Antigen-Loaded Extracellular Vesicles Induce Responsiveness to Anti–PD-1 and Anti–PD-L1 Treatment in a Checkpoint Refractory Melanoma Model
Upregulation of functional markers on DCs after in vitro exposure to EVs.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Figure 2 from Antigen-Loaded Extracellular Vesicles Induce Responsiveness to Anti–PD-1 and Anti–PD-L1 Treatment in a Checkpoint Refractory Melanoma Model
Combination treatment of EVs and anti–PD-1/anti–PD-L1 improves antitumor immunity on day 20 after tumor inoculation. A, Mice with OVA-expressing B16 melanoma were treated with PBS or EVs intravenously and anti–PD-1/PD-L1 intraperitoneally as indicated. Mice were sacrificed on day 20 for further analysis. B, Tumor volume was measured on day 20. C, The total number of OVA-specific CD8+ T cells in the spleen was determined using flow cytometry. D, ELISPOT assay was performed to detect IFNγ-secreting cells after in vitro restimulation with the CD4 peptide OVA323–339, CD8 peptide SIINFEKL, whole OVA protein, or B16 melanoma cells. The data represent one experiment. Dots represent a single mouse, 4 to 5 mice per group, and data are presented as the mean ± SEM, except for figure 2C which is displayed as the mean ± SD. Data were analyzed using the Kruskal–Wallis test with Dunn test for multiple comparisons. *, P < 0.05; **, P < 0.01; and ***, P < 0.001.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Antigen-Loaded Extracellular Vesicles Induce Responsiveness to Anti–PD-1 and Anti–PD-L1 Treatment in a Checkpoint Refractory Melanoma Model
Combination treatment of EVs and anti–PD-1/anti–PD-L1 improves antitumor immunity on day 20 after tumor inoculation. A, Mice with OVA-expressing B16 melanoma were treated with PBS or EVs intravenously and anti–PD-1/PD-L1 intraperitoneally as indicated. Mice were sacrificed on day 20 for further analysis. B, Tumor volume was measured on day 20. C, The total number of OVA-specific CD8+ T cells in the spleen was determined using flow cytometry. D, ELISPOT assay was performed to detect IFNγ-secreting cells after in vitro restimulation with the CD4 peptide OVA323–339, CD8 peptide SIINFEKL, whole OVA protein, or B16 melanoma cells. The data represent one experiment. Dots represent a single mouse, 4 to 5 mice per group, and data are presented as the mean ± SEM, except for figure 2C which is displayed as the mean ± SD. Data were analyzed using the Kruskal–Wallis test with Dunn test for multiple comparisons. *, P < 0.05; **, P < 0.01; and ***, P < 0.001.